3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
3
Glioblastoma
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Malignant Solid Neoplasm
1
Kidney Neoplasms
1
Ischemic Stroke
1
Hypoxia
1
Hemorrhagic Stroke
1
Head and Neck Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Childhood Brain Neoplasm
1
Central Nervous System Vascular Malformations
1
Central Nervous System Infections
1
Carcinoma, Medullary
1
Cancer of Lymph Node
1
Interventions
Filgrastim
5
Ifosfamide
3
Docetaxel
3
Carboplatin
3
belinostat
2
Sunitinib
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Gemcitabine
2
Etoposide
2
Epirubicin
2
Doxorubicin
2
toripalimab
1
temsirolimus
1
tanespimycin
1
resiquimod
1
poly ICLC
1
perifosine
1
pegfilgrastim
1
pazopanib
1
liposomal doxorubicin
1
ivosidenib
1
etoposide phosphate
1
enasidenib
1
apatinib
1
angiotensin I (1-7)
1
alanosine
1
Vincristine
1
Topotecan
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Chondrosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts